AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 151 min read$CLLS

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Cellectis (NASDAQ:CL

Analysts downgraded several stocks: HSBC cut Banco Santander Brasil (BSBR) to Hold with a $6.2 target; Rosenblatt downgraded Ribbon Communications (RBBN) to Neutral with a $2.2 target; Citizens downgraded Cellectis (CLLS) to Market Perform; Barclays downgraded Scholar Rock (SRRK) to Equal-Weight with a $58 target; Raymond James downgraded Ascendis Pharma (ASND) to Outperform with a $287 target.

Original reporting
benzinga.com
Published Sep 15, 2026, 2:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 5:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CLLS
Bearish
medium confidence
Mentioned
$CLLS · $BSBR · $RBBN · $SRRK · $ASND
Relevance
6/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$CLLSBearishMed
01

Why it matters

The downgrades may lead to short-term price pressure on the affected stocks, though the overall market impact is limited.

02

Market read

Downgrades may trigger modest sell-offs in the listed stocks, with limited broader market effect.

03

What to watch

Potential upcoming earnings or sector catalysts could offset downgrade effects.

Relevance 6/10Novelty 6/10Timing: after Monday close

Background

Analyst rating changes are a routine part of market coverage, reflecting updated views on company prospects.

Company-level read

Ticker impact

$CLLSBearishMedium confidence
Context

Cellectis (NASDAQ:CLLS) was downgraded from Market Outperform to Market Perform.

Expected impact

Potential short-term decline

Evidence & confidence

Downgrade signals weaker outlook, likely prompting sell pressure.

$BSBRNeutralMedium confidence
Context

Banco Santander Brasil (NYSE:BSBR) was downgraded from Buy to Hold.

Expected impact

Flat to slight down

Evidence & confidence

Hold suggests no further upside, may temper buying.

$RBBNBearishMedium confidence
Context

Ribbon Communications (NASDAQ:RBBN) was downgraded from Buy to Neutral.

Expected impact

Possible modest decline

Evidence & confidence

Neutral stance often leads to reduced demand.

$SRRKNeutralMedium confidence
Context

Scholar Rock Holding (NASDAQ:SRRK) was downgraded from Overweight to Equal-Weight.

Expected impact

Flat to slight down

Evidence & confidence

Equal-Weight is a neutral stance, limiting upside.

$ASNDNeutralMedium confidence
Context

Ascendis Pharma (NASDAQ:ASND) was downgraded from Strong Buy to Outperform.

Expected impact

Flat to modest decline

Evidence & confidence

Reduced rating may temper enthusiasm.

Market effects

Sector

Analyst downgrades across diverse sectors may signal broader caution.

Regional

Primarily U.S. listed equities; limited regional effect.

Global

Low global impact beyond individual stocks.

Counterpoint

What could challenge this read

Some investors may view the downgrades as overreaction and look for buying opportunities.

Key entities

  • company
    Cellectis SA

    Biotech firm focused on gene editing.

  • company
    Banco Santander Brasil

    Brazilian banking subsidiary of Santander.

  • company
    Ribbon Communications

    Provider of communications software.

  • company
    Scholar Rock Holding Corp

    Life sciences contract research organization.

  • company
    Ascendis Pharma

    Biopharmaceutical company.

Read at source← All news

Related articles

SEP 28
$BMYHighAI 8/10

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

Bristol Myers Squibb (BMY) awaits an FDA decision on Sept. 30 for expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy. Egetis Therapeutics (EGTX) faces a Sept. 28 decision for Emcitate for MCT8 deficiency. Scholar Rock (SRRK), Biofrontera (BFRI), and Mirum Pharmaceuticals (MIRM) received early FDA approvals for their respective drugs. Mirum's shares rose 3% in pre-market trading.

newsable.asianetnews.com2 min
SEP 28
$BMYHighAI 8/10

FDA Decision Watch: BMY, EGTX Await Key Rulings As BFRI, SRRK, MIRM Win Early Approvals

Bristol Myers Squibb (BMY) and Egetis Therapeutics (EGTX) await FDA decisions on drug expansions. Biofrontera (BFRI), Scholar Rock (SRRK), and Mirum Pharmaceuticals (MIRM) received early approvals. BMY's Camzyos, if approved, would be the first cardiac myosin inhibitor for adolescents with oHCM. EGTX's Emcitate could be the first FDA-approved treatment for MCT8 deficiency. SRRK and BFRI shares declined post-approval, while MIRM shares rose.

stocktwits.com2 min
SEP 22
$NVOMed

Weight-loss drug developers line up to tap lucrative market

The weight-loss drug market is growing rapidly, with analysts projecting $100B in annual sales in the next decade. Novo Nordisk and Eli Lilly lead the sector, but other companies like Pfizer, Viking Therapeutics, and AstraZeneca are developing new treatments. Key drugs include Novo's amycretin and CagriSema, Pfizer's PF-3944, and Lilly's retatrutide, with varying degrees of success in clinical trials.

tucson.com3 min
SEP 21
$ASNDHigh

Ascendis Pharma (ASND) Authorizes $400M Share Buyback

Ascendis Pharma (ASND) authorized a $400M share buyback. Q2 2025 saw €315M product revenue, up 105% YoY, with €220M operating profit. Cash reserves grew to €812M. Buyback is discretionary, dependent on market conditions. YORVIPATH drove most revenue, while SKYTROFA and YUVIWEL contributed less. Costs increased due to expansion and R&D.

finance.yahoo.com2 min